Ocugen receives unanimous FDA approval on key aspects of pivotal Phase 3 study design for OCU400 modified gene therapy

Ocugen receives unanimous FDA approval on key aspects of pivotal Phase 3 study design for OCU400 modified gene therapy

Okugan MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) is a biotechnology company focused on the discovery, development and commercialization of novel …

Read more